Remove Cosmetics Remove Drugs Remove Pharmacy
article thumbnail

DCGI issues show cause notice to e-pharmacies for stocking & selling drugs in contravention to D&C Act

AuroBlog - Aurous Healthcare Clinical Trials blog

The Drug Controller General of India (DCGI) has issued a show cause notice to online pharmacies including Tata 1mg for allegedly stocking and selling drugs in contravention of the provisions of the Drugs and Cosmetics Act, 1940 and Rules, once again bringing back the long pending issue of lack of regulations on e-pharmacies under the […]

Pharmacy 144
article thumbnail

The Drugs and Cosmetics Act, 1940: Genesis to Zenith

Pharma Tutor

The Drugs and Cosmetics Act, 1940: Genesis to Zenith admin Tue, 04/04/2023 - 16:00 ABOUT AUTHOR Dr. R. Thakur Chief Editor, Journal of Pharmaceutical Research Krupanidhi College of Pharmacy, Bengaluru, India. Email : drramsthakur@gmail.com

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TN DCA issues circular asking pharmacists in medical shops to wear white coat and badges

AuroBlog - Aurous Healthcare Clinical Trials blog

Although provisions of the Pharmacy Practice Regulations (PPR) 2015 are not there in the Drugs and Cosmetics (D&C) Act 1940 but are framed under the Pharmacy Act 1948, the steps now being taken by the drugs control administration (DCA) in Tamil Nadu in a motive to strengthen the dispensing activities in pharmacies are completely agreeing […] (..)

Cosmetics 162
article thumbnail

Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount

Fierce Pharma

Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other issues such as high prices and off-label co | Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy.

Cosmetics 123
article thumbnail

Arkansas Law Prohibiting Manufacturer 340B Contract Pharmacy Restrictions Upheld by 8th Circuit

FDA Law Blog

By Faraz Siddiqui — As drug manufacturers battle the Health Resources and Services Administration (“HRSA”) in federal courts over the role of 340B contract pharmacies, an Eighth Circuit decision to uphold a 2021 Arkansas law may render those cases inconsequential in that state. Code Ann. § 23-92-604(c)(1), (2) (Act 1103).

article thumbnail

D.C. Circuit Sides with Manufacturers in Latest 340B Contract Pharmacy Case

FDA Law Blog

Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceutical manufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. In United Therapeutics Corporation v.

article thumbnail

The D.C. District Court Slaps Down on Procedural Grounds FDA’s 20-year Effort to Implement its Memorandum of Understanding to Address Interstate Shipments of Compounded Drug Products

FDA Law Blog

This time, “David” consists of a cast of seven compounding pharmacies and their amicus curiae supporters. See Federal Food, Drug, and Cosmetic Act (“FDCA”) Section 503A(b)(2). In signatory states, compounding pharmacies are subject to a 50% “threshold” and certain reporting requirements.